Ignite Creation Date:
2024-07-17 @ 11:15 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06485271
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2024-06-26
Brief Title:
A Real-world Study of Camrelizumab Alone or in Combination With ApatinibChemotherapy for Advanced Gastric Cancer
Sponsor:
Changzhi Peoples Hospital Affiliated to Changzhi Medical College
Organization:
Changzhi Peoples Hospital Affiliated to Changzhi Medical College
Study Overview
Official Title:
A Real-world Study of Camrelizumab Alone or in Combination With ApatinibChemotherapy for Advanced Gastric Cancer
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this observational study is to evaluate the safety and efficacy of camrelizumab and apatinib in patients with advanced gastric cancer under real-life conditions particularly in various subgroups of gastric cancer patients with a view to providing information about the treatment modalities and efficacy of the treatment in real-life gastric cancer patients and to explore the possible predictive biomarkers of prognosisPatients who had both decided to be treated with camrelizumab or apatinib prior to enrollment were entered into one of the following three cohorts at the discretion of the investigator based on their disease stage and prior treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None